Literature DB >> 20437464

Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited.

Weirong Wang1, Thomayant Prueksaritanont.   

Abstract

In this report, the utility of a commonly used interspecies scaling method to predict the systemic clearance (CL) of therapeutic proteins in humans was evaluated. Based on analysis of a pharmacokinetic data set of 34 therapeutic proteins, including 12 monoclonal antibodies (mAbs) and Fc fusion proteins, human CL can generally be predicted reasonably well with simple allometric scaling and a fixed exponent of 0.8: approximately 95% of the cases predicted values within 2-fold of the observed values when using CL data from multiple species, or approximately 90% simply using CL from monkeys. Specific to mAbs/Fc fusion proteins, scaling from monkey CL using a fixed exponent of 0.8 gave an excellent prediction; all predicted CL values were within 2-fold of the corresponding observed values. Compared with the simple allometric scaling method that uses a fitted exponent from CL data of > or =3 preclinical species, the fixed exponent approach with 1-2 preclinical species is simple, resource-saving and minimizes systematic bias. Together with its overall satisfactory prediction accuracy, especially in the absence of non-linear pharmacokinetics and species-specific clearance mechanisms, this fixed exponent method affords a viable alternative to other published allometric methods, including the Rule of Exponents (ROE). Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437464     DOI: 10.1002/bdd.708

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  36 in total

Review 1.  ADME of biologics-what have we learned from small molecules?

Authors:  Thomayant Prueksaritanont; Cuyue Tang
Journal:  AAPS J       Date:  2012-04-07       Impact factor: 4.009

Review 2.  Mechanistic determinants of biotherapeutics absorption following SC administration.

Authors:  Wolfgang F Richter; Suraj G Bhansali; Marilyn E Morris
Journal:  AAPS J       Date:  2012-05-23       Impact factor: 4.009

3.  Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.

Authors:  Leonid Kagan; Jie Zhao; Donald E Mager
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

4.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

5.  From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

Authors:  Jing Yu; Helene Karcher; Adam L Feire; Philip J Lowe
Journal:  AAPS J       Date:  2011-02-19       Impact factor: 4.009

6.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

7.  Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Authors:  Aman P Singh; Wojciech Krzyzanski; Steven W Martin; Gregory Weber; Alison Betts; Alaa Ahmad; Anson Abraham; Anup Zutshi; John Lin; Pratap Singh
Journal:  AAPS J       Date:  2014-12-03       Impact factor: 4.009

Review 8.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

9.  A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide.

Authors:  Elliot Offman; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-04       Impact factor: 2.745

Review 10.  Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Authors:  Y Zhang; S Doshi; M Zhu
Journal:  Br J Clin Pharmacol       Date:  2015-05-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.